The liquid Kangfuxin (KFX) has efficient antifungal activity and can be used in the treatment of vulvovaginal candidiasis in mice
Vulvovaginal candidiasis (VVC) is an infectious disease caused mainly by Candida albicans. Kangfuxin (KFX) is a traditional Chinese medicine preparation made from Periplaneta americana extracts, which promotes wound healing and enhances body immunity and also acts as an antifungal agent. Here, we ev...
Gespeichert in:
| Veröffentlicht in: | Letters in applied microbiology 2022-04, Vol.74 (4), p.564-576 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 576 |
|---|---|
| container_issue | 4 |
| container_start_page | 564 |
| container_title | Letters in applied microbiology |
| container_volume | 74 |
| creator | Ma, J. Yang, Y.‐C. Su, L.‐Q. Qin, D.‐M. Yuan, K. Zhang, Y. Wang, R.‐R. |
| description | Vulvovaginal candidiasis (VVC) is an infectious disease caused mainly by Candida albicans. Kangfuxin (KFX) is a traditional Chinese medicine preparation made from Periplaneta americana extracts, which promotes wound healing and enhances body immunity and also acts as an antifungal agent. Here, we evaluated the effect of KFX in the treatment of VVC in vitro and in vivo. The minimum inhibitory concentration (MIC50) of KFX against C. albicans ranged from 7·65 to 20·57%. In addition, KFX was more efficient than fluconazole (FLC) in inhibiting the drug‐resistant C. albicans, and the effect was more intense after 8 h. The KFX treatment also exhibited good activity in vivo. It restored the body weight and reduced the vulvovaginal symptoms in mice induced with VVC. It downregulated the expression of the hyphae‐related gene, HWP1, thus inhibiting the growth and development of C. albicans hyphae. It also increased the number of neutrophils and promoted the secretion of interleukin‐17A (IL‐17A); however, the levels of interleukin‐8 (IL‐8) and interleukin‐1β (IL‐1β) decreased in mice with VVC. We deduce that KFX effectively treats vaginal candidiasis in two ways: by inhibiting the growth and development of mycelia to reduce colonization of C. albicans and by promoting the secretion and release of IL‐17A and neutrophils in high numbers to fight C. albicans infection. This study provides a theoretical basis for the use of KFX for the clinical treatment of VVC.
Significance and Impact of the Study: Vulvovaginal candidiasis (VVC) is an infectious disease of the female external reproductive tract, caused by the ecological imbalance in the vagina due to the influence of various pathogenic factors, which brings harm to women's physical and mental health. However, the availability of drugs is limited and the frequency of drug‐resistant Candida isolates is increasing. It is urgent to find new drugs or effective treatment strategies. We found that Kangfuxin liquid (KFX) can be used to treat VVC by reducing mycelial growth and boosting immunity, which presents a new clinical alternative. |
| doi_str_mv | 10.1111/lam.13641 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2615122743</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2639037936</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3531-ccaf470527a7119b6cd096c0fd7dbc3c954a02d967fd7bf5283161ff9bb759953</originalsourceid><addsrcrecordid>eNp10ctKAzEUBuAgitbLwheQgJu6mJrLJGmWUqyKFTcK3Q2ZXGpkLjqZVLv0zU2tuhDM5sDhOz-BH4BjjEY4vfNK1SNMeY63wADngmSCs_k2GCDCeTYmLN8D-yE8I4TGmMhdsEdzycYC0QH4eHiysPKv0Rt4q5qFi---gcPb6fwMPqkArXNee9v0UDW9d7FZqAoq3ful71dpZ6BWDSwtjMEamE77lNd3VvX1-qh1cBmrZbtUC9-ky4SNN14FH9a49toegh2nqmCPvucBeJxePkyus9n91c3kYpZpyijOtFYuF4gRoQTGsuTaIMk1ckaYUlMtWa4QMZKLtCkdI2OKOXZOlqVgUjJ6AIab3JeufY029EXtg7ZVpRrbxlAQjhkmROQ00dM_9LmNXfr_WlGJqJCUJ3W2UbprQ-isK146X6tuVWBUrHspUi_FVy_JnnwnxrK25lf-FJHA-Qa8-cqu_k8qZhd3m8hPqZiXLQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2639037936</pqid></control><display><type>article</type><title>The liquid Kangfuxin (KFX) has efficient antifungal activity and can be used in the treatment of vulvovaginal candidiasis in mice</title><source>Oxford University Press Journals All Titles (1996-Current)</source><source>MEDLINE</source><source>Wiley Online Library All Journals</source><creator>Ma, J. ; Yang, Y.‐C. ; Su, L.‐Q. ; Qin, D.‐M. ; Yuan, K. ; Zhang, Y. ; Wang, R.‐R.</creator><creatorcontrib>Ma, J. ; Yang, Y.‐C. ; Su, L.‐Q. ; Qin, D.‐M. ; Yuan, K. ; Zhang, Y. ; Wang, R.‐R.</creatorcontrib><description>Vulvovaginal candidiasis (VVC) is an infectious disease caused mainly by Candida albicans. Kangfuxin (KFX) is a traditional Chinese medicine preparation made from Periplaneta americana extracts, which promotes wound healing and enhances body immunity and also acts as an antifungal agent. Here, we evaluated the effect of KFX in the treatment of VVC in vitro and in vivo. The minimum inhibitory concentration (MIC50) of KFX against C. albicans ranged from 7·65 to 20·57%. In addition, KFX was more efficient than fluconazole (FLC) in inhibiting the drug‐resistant C. albicans, and the effect was more intense after 8 h. The KFX treatment also exhibited good activity in vivo. It restored the body weight and reduced the vulvovaginal symptoms in mice induced with VVC. It downregulated the expression of the hyphae‐related gene, HWP1, thus inhibiting the growth and development of C. albicans hyphae. It also increased the number of neutrophils and promoted the secretion of interleukin‐17A (IL‐17A); however, the levels of interleukin‐8 (IL‐8) and interleukin‐1β (IL‐1β) decreased in mice with VVC. We deduce that KFX effectively treats vaginal candidiasis in two ways: by inhibiting the growth and development of mycelia to reduce colonization of C. albicans and by promoting the secretion and release of IL‐17A and neutrophils in high numbers to fight C. albicans infection. This study provides a theoretical basis for the use of KFX for the clinical treatment of VVC.
Significance and Impact of the Study: Vulvovaginal candidiasis (VVC) is an infectious disease of the female external reproductive tract, caused by the ecological imbalance in the vagina due to the influence of various pathogenic factors, which brings harm to women's physical and mental health. However, the availability of drugs is limited and the frequency of drug‐resistant Candida isolates is increasing. It is urgent to find new drugs or effective treatment strategies. We found that Kangfuxin liquid (KFX) can be used to treat VVC by reducing mycelial growth and boosting immunity, which presents a new clinical alternative.</description><identifier>ISSN: 0266-8254</identifier><identifier>EISSN: 1472-765X</identifier><identifier>DOI: 10.1111/lam.13641</identifier><identifier>PMID: 34958703</identifier><language>eng</language><publisher>England: Oxford University Press</publisher><subject>Animals ; antifungal ; Antifungal activity ; Antifungal Agents - pharmacology ; Antifungal Agents - therapeutic use ; Body weight ; Candida albicans ; Candidiasis ; Candidiasis, Vulvovaginal - drug therapy ; Candidiasis, Vulvovaginal - microbiology ; Colonization ; Cytokines ; Female ; Fluconazole ; Fluconazole - pharmacology ; Fluconazole - therapeutic use ; Fungicides ; Health services ; Herbal medicine ; Hyphae ; Infectious diseases ; Interleukins ; Kangfuxin liquid ; Leukocytes (neutrophilic) ; Materia Medica - pharmacology ; Materia Medica - therapeutic use ; Mice ; Minimum inhibitory concentration ; murine model ; Mycelia ; Neutrophils ; Signs and symptoms ; Traditional Chinese medicine ; vaginal candidiasis ; Weight reduction ; Wound healing</subject><ispartof>Letters in applied microbiology, 2022-04, Vol.74 (4), p.564-576</ispartof><rights>2021 The Society for Applied Microbiology</rights><rights>2021 The Society for Applied Microbiology.</rights><rights>Copyright © 2022 The Society for Applied Microbiology</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3531-ccaf470527a7119b6cd096c0fd7dbc3c954a02d967fd7bf5283161ff9bb759953</citedby><cites>FETCH-LOGICAL-c3531-ccaf470527a7119b6cd096c0fd7dbc3c954a02d967fd7bf5283161ff9bb759953</cites><orcidid>0000-0003-3014-012X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Flam.13641$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Flam.13641$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34958703$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ma, J.</creatorcontrib><creatorcontrib>Yang, Y.‐C.</creatorcontrib><creatorcontrib>Su, L.‐Q.</creatorcontrib><creatorcontrib>Qin, D.‐M.</creatorcontrib><creatorcontrib>Yuan, K.</creatorcontrib><creatorcontrib>Zhang, Y.</creatorcontrib><creatorcontrib>Wang, R.‐R.</creatorcontrib><title>The liquid Kangfuxin (KFX) has efficient antifungal activity and can be used in the treatment of vulvovaginal candidiasis in mice</title><title>Letters in applied microbiology</title><addtitle>Lett Appl Microbiol</addtitle><description>Vulvovaginal candidiasis (VVC) is an infectious disease caused mainly by Candida albicans. Kangfuxin (KFX) is a traditional Chinese medicine preparation made from Periplaneta americana extracts, which promotes wound healing and enhances body immunity and also acts as an antifungal agent. Here, we evaluated the effect of KFX in the treatment of VVC in vitro and in vivo. The minimum inhibitory concentration (MIC50) of KFX against C. albicans ranged from 7·65 to 20·57%. In addition, KFX was more efficient than fluconazole (FLC) in inhibiting the drug‐resistant C. albicans, and the effect was more intense after 8 h. The KFX treatment also exhibited good activity in vivo. It restored the body weight and reduced the vulvovaginal symptoms in mice induced with VVC. It downregulated the expression of the hyphae‐related gene, HWP1, thus inhibiting the growth and development of C. albicans hyphae. It also increased the number of neutrophils and promoted the secretion of interleukin‐17A (IL‐17A); however, the levels of interleukin‐8 (IL‐8) and interleukin‐1β (IL‐1β) decreased in mice with VVC. We deduce that KFX effectively treats vaginal candidiasis in two ways: by inhibiting the growth and development of mycelia to reduce colonization of C. albicans and by promoting the secretion and release of IL‐17A and neutrophils in high numbers to fight C. albicans infection. This study provides a theoretical basis for the use of KFX for the clinical treatment of VVC.
Significance and Impact of the Study: Vulvovaginal candidiasis (VVC) is an infectious disease of the female external reproductive tract, caused by the ecological imbalance in the vagina due to the influence of various pathogenic factors, which brings harm to women's physical and mental health. However, the availability of drugs is limited and the frequency of drug‐resistant Candida isolates is increasing. It is urgent to find new drugs or effective treatment strategies. We found that Kangfuxin liquid (KFX) can be used to treat VVC by reducing mycelial growth and boosting immunity, which presents a new clinical alternative.</description><subject>Animals</subject><subject>antifungal</subject><subject>Antifungal activity</subject><subject>Antifungal Agents - pharmacology</subject><subject>Antifungal Agents - therapeutic use</subject><subject>Body weight</subject><subject>Candida albicans</subject><subject>Candidiasis</subject><subject>Candidiasis, Vulvovaginal - drug therapy</subject><subject>Candidiasis, Vulvovaginal - microbiology</subject><subject>Colonization</subject><subject>Cytokines</subject><subject>Female</subject><subject>Fluconazole</subject><subject>Fluconazole - pharmacology</subject><subject>Fluconazole - therapeutic use</subject><subject>Fungicides</subject><subject>Health services</subject><subject>Herbal medicine</subject><subject>Hyphae</subject><subject>Infectious diseases</subject><subject>Interleukins</subject><subject>Kangfuxin liquid</subject><subject>Leukocytes (neutrophilic)</subject><subject>Materia Medica - pharmacology</subject><subject>Materia Medica - therapeutic use</subject><subject>Mice</subject><subject>Minimum inhibitory concentration</subject><subject>murine model</subject><subject>Mycelia</subject><subject>Neutrophils</subject><subject>Signs and symptoms</subject><subject>Traditional Chinese medicine</subject><subject>vaginal candidiasis</subject><subject>Weight reduction</subject><subject>Wound healing</subject><issn>0266-8254</issn><issn>1472-765X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp10ctKAzEUBuAgitbLwheQgJu6mJrLJGmWUqyKFTcK3Q2ZXGpkLjqZVLv0zU2tuhDM5sDhOz-BH4BjjEY4vfNK1SNMeY63wADngmSCs_k2GCDCeTYmLN8D-yE8I4TGmMhdsEdzycYC0QH4eHiysPKv0Rt4q5qFi---gcPb6fwMPqkArXNee9v0UDW9d7FZqAoq3ful71dpZ6BWDSwtjMEamE77lNd3VvX1-qh1cBmrZbtUC9-ky4SNN14FH9a49toegh2nqmCPvucBeJxePkyus9n91c3kYpZpyijOtFYuF4gRoQTGsuTaIMk1ckaYUlMtWa4QMZKLtCkdI2OKOXZOlqVgUjJ6AIab3JeufY029EXtg7ZVpRrbxlAQjhkmROQ00dM_9LmNXfr_WlGJqJCUJ3W2UbprQ-isK146X6tuVWBUrHspUi_FVy_JnnwnxrK25lf-FJHA-Qa8-cqu_k8qZhd3m8hPqZiXLQ</recordid><startdate>202204</startdate><enddate>202204</enddate><creator>Ma, J.</creator><creator>Yang, Y.‐C.</creator><creator>Su, L.‐Q.</creator><creator>Qin, D.‐M.</creator><creator>Yuan, K.</creator><creator>Zhang, Y.</creator><creator>Wang, R.‐R.</creator><general>Oxford University Press</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7QO</scope><scope>7ST</scope><scope>7T7</scope><scope>7TM</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>M7N</scope><scope>P64</scope><scope>SOI</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-3014-012X</orcidid></search><sort><creationdate>202204</creationdate><title>The liquid Kangfuxin (KFX) has efficient antifungal activity and can be used in the treatment of vulvovaginal candidiasis in mice</title><author>Ma, J. ; Yang, Y.‐C. ; Su, L.‐Q. ; Qin, D.‐M. ; Yuan, K. ; Zhang, Y. ; Wang, R.‐R.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3531-ccaf470527a7119b6cd096c0fd7dbc3c954a02d967fd7bf5283161ff9bb759953</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Animals</topic><topic>antifungal</topic><topic>Antifungal activity</topic><topic>Antifungal Agents - pharmacology</topic><topic>Antifungal Agents - therapeutic use</topic><topic>Body weight</topic><topic>Candida albicans</topic><topic>Candidiasis</topic><topic>Candidiasis, Vulvovaginal - drug therapy</topic><topic>Candidiasis, Vulvovaginal - microbiology</topic><topic>Colonization</topic><topic>Cytokines</topic><topic>Female</topic><topic>Fluconazole</topic><topic>Fluconazole - pharmacology</topic><topic>Fluconazole - therapeutic use</topic><topic>Fungicides</topic><topic>Health services</topic><topic>Herbal medicine</topic><topic>Hyphae</topic><topic>Infectious diseases</topic><topic>Interleukins</topic><topic>Kangfuxin liquid</topic><topic>Leukocytes (neutrophilic)</topic><topic>Materia Medica - pharmacology</topic><topic>Materia Medica - therapeutic use</topic><topic>Mice</topic><topic>Minimum inhibitory concentration</topic><topic>murine model</topic><topic>Mycelia</topic><topic>Neutrophils</topic><topic>Signs and symptoms</topic><topic>Traditional Chinese medicine</topic><topic>vaginal candidiasis</topic><topic>Weight reduction</topic><topic>Wound healing</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ma, J.</creatorcontrib><creatorcontrib>Yang, Y.‐C.</creatorcontrib><creatorcontrib>Su, L.‐Q.</creatorcontrib><creatorcontrib>Qin, D.‐M.</creatorcontrib><creatorcontrib>Yuan, K.</creatorcontrib><creatorcontrib>Zhang, Y.</creatorcontrib><creatorcontrib>Wang, R.‐R.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Environment Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Nucleic Acids Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environment Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Letters in applied microbiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ma, J.</au><au>Yang, Y.‐C.</au><au>Su, L.‐Q.</au><au>Qin, D.‐M.</au><au>Yuan, K.</au><au>Zhang, Y.</au><au>Wang, R.‐R.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The liquid Kangfuxin (KFX) has efficient antifungal activity and can be used in the treatment of vulvovaginal candidiasis in mice</atitle><jtitle>Letters in applied microbiology</jtitle><addtitle>Lett Appl Microbiol</addtitle><date>2022-04</date><risdate>2022</risdate><volume>74</volume><issue>4</issue><spage>564</spage><epage>576</epage><pages>564-576</pages><issn>0266-8254</issn><eissn>1472-765X</eissn><abstract>Vulvovaginal candidiasis (VVC) is an infectious disease caused mainly by Candida albicans. Kangfuxin (KFX) is a traditional Chinese medicine preparation made from Periplaneta americana extracts, which promotes wound healing and enhances body immunity and also acts as an antifungal agent. Here, we evaluated the effect of KFX in the treatment of VVC in vitro and in vivo. The minimum inhibitory concentration (MIC50) of KFX against C. albicans ranged from 7·65 to 20·57%. In addition, KFX was more efficient than fluconazole (FLC) in inhibiting the drug‐resistant C. albicans, and the effect was more intense after 8 h. The KFX treatment also exhibited good activity in vivo. It restored the body weight and reduced the vulvovaginal symptoms in mice induced with VVC. It downregulated the expression of the hyphae‐related gene, HWP1, thus inhibiting the growth and development of C. albicans hyphae. It also increased the number of neutrophils and promoted the secretion of interleukin‐17A (IL‐17A); however, the levels of interleukin‐8 (IL‐8) and interleukin‐1β (IL‐1β) decreased in mice with VVC. We deduce that KFX effectively treats vaginal candidiasis in two ways: by inhibiting the growth and development of mycelia to reduce colonization of C. albicans and by promoting the secretion and release of IL‐17A and neutrophils in high numbers to fight C. albicans infection. This study provides a theoretical basis for the use of KFX for the clinical treatment of VVC.
Significance and Impact of the Study: Vulvovaginal candidiasis (VVC) is an infectious disease of the female external reproductive tract, caused by the ecological imbalance in the vagina due to the influence of various pathogenic factors, which brings harm to women's physical and mental health. However, the availability of drugs is limited and the frequency of drug‐resistant Candida isolates is increasing. It is urgent to find new drugs or effective treatment strategies. We found that Kangfuxin liquid (KFX) can be used to treat VVC by reducing mycelial growth and boosting immunity, which presents a new clinical alternative.</abstract><cop>England</cop><pub>Oxford University Press</pub><pmid>34958703</pmid><doi>10.1111/lam.13641</doi><tpages>576</tpages><orcidid>https://orcid.org/0000-0003-3014-012X</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0266-8254 |
| ispartof | Letters in applied microbiology, 2022-04, Vol.74 (4), p.564-576 |
| issn | 0266-8254 1472-765X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2615122743 |
| source | Oxford University Press Journals All Titles (1996-Current); MEDLINE; Wiley Online Library All Journals |
| subjects | Animals antifungal Antifungal activity Antifungal Agents - pharmacology Antifungal Agents - therapeutic use Body weight Candida albicans Candidiasis Candidiasis, Vulvovaginal - drug therapy Candidiasis, Vulvovaginal - microbiology Colonization Cytokines Female Fluconazole Fluconazole - pharmacology Fluconazole - therapeutic use Fungicides Health services Herbal medicine Hyphae Infectious diseases Interleukins Kangfuxin liquid Leukocytes (neutrophilic) Materia Medica - pharmacology Materia Medica - therapeutic use Mice Minimum inhibitory concentration murine model Mycelia Neutrophils Signs and symptoms Traditional Chinese medicine vaginal candidiasis Weight reduction Wound healing |
| title | The liquid Kangfuxin (KFX) has efficient antifungal activity and can be used in the treatment of vulvovaginal candidiasis in mice |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T04%3A39%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20liquid%20Kangfuxin%20(KFX)%20has%20efficient%20antifungal%20activity%20and%20can%20be%20used%20in%20the%20treatment%20of%20vulvovaginal%20candidiasis%20in%20mice&rft.jtitle=Letters%20in%20applied%20microbiology&rft.au=Ma,%20J.&rft.date=2022-04&rft.volume=74&rft.issue=4&rft.spage=564&rft.epage=576&rft.pages=564-576&rft.issn=0266-8254&rft.eissn=1472-765X&rft_id=info:doi/10.1111/lam.13641&rft_dat=%3Cproquest_cross%3E2639037936%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2639037936&rft_id=info:pmid/34958703&rfr_iscdi=true |